FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Preferred Pharmaceuticals Diclofenac Sodium Topical Solution 1 Recall

Diclofenac Sodium Topical Solution 1

Preferred Pharmaceuticals, Inc. · Anaheim, CA

Risk level
Class II
Reported by FDA
Apr 27, 2022
Recall ID
D-0773-2022
Check your lot numberHow we source this data

Summary

Preferred Pharmaceuticals recalled Diclofenac Sodium Topical Solution 1 starting Mar 24, 2022. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0773-2022 on Apr 27, 2022. Reason: CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc. is discontinuing its stability study program. Status: Terminated.

Why it was recalled

CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc. is discontinuing its stability study program.

Product description

Diclofenac Sodium Topical Solution 1.5% w/w, Generic for Pennsaid, 150 ml bottle, Rx Only, Mfg: Sola Pharmaceutical, Preferred Pharmaceuticals, Inc., The Physicians Solutions, NDC 68788-7918-01

Lot numbers, UPCs & expiration codes

Lots: E1220B, Exp.: 01/31/2023; F0220M, Exp.: 3/31/2023; F2320A, Exp.: 3/31/2023; F3020M, Exp.: 3/31/2023; G0920Q, Exp.: 3/31/2023; C0821M, Exp.: 1/31/2024; J1920, Exp.: 5/31/2023; E2421j, Exp.: 4/30/2024

Where it was sold

Nationwide within the USA.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0773-2022
Classification
Class II
Status
Terminated
Recall initiated
Mar 24, 2022
FDA report date
Apr 27, 2022
Quantity
528 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Preferred Pharmaceuticals, Inc.

Original FDA data

Every field from FDA enforcement report D-0773-2022, exactly as published.

Show all FDA fields
City
Anaheim
State
CA
Status
Terminated
Country
United States
Event ID
89945
Address
1250 N Lakeview Ave Ste O
Code information
Lots: E1220B, Exp.: 01/31/2023; F0220M, Exp.: 3/31/2023; F2320A, Exp.: 3/31/2023; F3020M, Exp.: 3/31/2023; G0920Q, Exp.: 3/31/2023; C0821M, Exp.: 1/31/2024; J1920, Exp.: 5/31/2023; E2421j, Exp.: 4/30/2024
Postal code
92807-1801
Report date
Apr 27, 2022
Product type
Drugs
Recall number
D-0773-2022
Classification
Class II
Recalling firm
Preferred Pharmaceuticals, Inc.
Product quantity
528 bottles
Termination date
Oct 25, 2023
Reason for recall
CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc. is discontinuing its stability study program.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Diclofenac Sodium Topical Solution 1.5% w/w, Generic for Pennsaid, 150 ml bottle, Rx Only, Mfg: Sola Pharmaceutical, Preferred Pharmaceuticals, Inc., The Physicians Solutions, NDC 68788-7918-01
Distribution pattern
Nationwide within the USA.
Recall initiation date
Mar 24, 2022
Initial firm notification
Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Center classification date
Apr 15, 2022

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0773-2022, published Apr 27, 2022. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls